Population pharmacokinetics of nirmatrelvir/ritonavir in critically ill Chinese COVID-19 patients and recommendations for medication use: a two-center retrospective study
Expert Review of Clinical Pharmacology · 2024
DOI: 10.1080/17512433.2024.2410385 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Expert Review of Clinical Pharmacology, 2024. Verfasst von Junjun Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Critical Illness, Monte Carlo Method, Ritonavir. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Zhejiang Provincial Natural Science Foundation of China, Zhejiang medicine and health science and technology, Hangzhou Medical and Health Science and Technology Project.
Abstract (Originalsprache)
BACKGROUND: This study aimed to establish population pharmacokinetics (PPK) models of nirmatrelvir/ritonavir in critically ill Chinese patients with the coronavirus disease 2019 (COVID-19) infection, explore factors affecting the pharmacokinetics (PK) of nirmatrelvir/ritonavir. METHODS: A total of 285 serum samples and clinical data were collected from 152 patients. The PPK models of nirmatrelvir/ritonavir were analyzed using nonlinear mixed-effect modeling (NONMEM) approach. The optimal dosing regimen for patients with different renal function was determined using Monte Carlo simulations. RESULTS: The population typical values of apparent clearance (CL/F) and apparent volume of distribution (V/F) of nirmatrelvir were 2.26 L/h and 15.3 L, respectively. Notably, creatinine clearance (CrCL) significantly influenced the PK variation of nirmatrelvir. Monte Carlo simulations suggested that patients with mild-to-moderate renal impairment experienced a 22.0-59.9% increase in the area under the curve (AUC) when they were administered a standard dose of nirmatrelvir compared to those with normal renal function. The AUC in patients with severe renal impairment after administration of 150 mg q12h nirmatrelvir was similar to that in patients with normal renal function after administration of 300 mg q12h nirmatrelvir. CONCLUSIONS: PPK modeling and simulation provided a reference for the rational clinical application of nirmatrelvir/ritonavir in critically ill Chinese patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
- Department of Pharmacy, Hangzhou Red Cross Hospital, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, Zhejiang Province, China.
ORCID-Profile: Junjun Xu
Förderung
- Zhejiang Provincial Natural Science Foundation of China
- Zhejiang medicine and health science and technology
- Hangzhou Medical and Health Science and Technology Project
- Zhejiang Province Traditional Chinese Medicine Science and Technology Project
Zitieren
APA
Xu, J., Li, J., Chen, M., Jiang, H., Fan, X., Hu, Y., Shan, H., Yang, M., Xu, Y., Lang, Y., Dai, H., & Cai, X. (2024). Population pharmacokinetics of nirmatrelvir/ritonavir in critically ill Chinese COVID-19 patients and recommendations for medication use: a two-center retrospective study. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2024.2410385
Vancouver
Xu J, Li J, Chen M, Jiang H, Fan X, Hu Y, et al. Population pharmacokinetics of nirmatrelvir/ritonavir in critically ill Chinese COVID-19 patients and recommendations for medication use: a two-center retrospective study. Expert Review of Clinical Pharmacology. 2024. doi:10.1080/17512433.2024.2410385
BibTeX
@article{Xu2024,
author = {Xu, Junjun and Li, Jinmeng and Chen, Meng and Jiang, Huifang and Fan, Xudong and Hu, Yangmin and Shan, Haili and Yang, Mingdong and Xu, Yichao and Lang, Yuying and Dai, Haibin and Cai, Xinjun},
title = {Population pharmacokinetics of nirmatrelvir/ritonavir in critically ill Chinese COVID-19 patients and recommendations for medication use: a two-center retrospective study},
journal = {Expert Review of Clinical Pharmacology},
year = {2024},
doi = {10.1080/17512433.2024.2410385}
}
EUVIMED